SBFM | tickerfilter.com

Fundamental analysis

19%

Profitability 0%

Dept financing 31%

Liquidity 75%

Performance 20%

Company vs Stock growth

9.303 M 8.435 M

-867.889 K -9.33%

2.980 2.860

-0.120 -4.03%

+ Add row to compare

Performance

5 Days

-19.02%

1 Month

-34.36%

3 Months

-49.83%

6 Months

-49.32%

1 Year

-84.61%

2 Year

124.06%

Key data

Stock price

$1.49

P/E Ratio

0.00

DAY RANGE

$1.25 - $1.50

EPS

-$11.94

52 WEEK RANGE

$0.15 - $10.00

52 WEEK CHANGE

-$84.40

MARKET CAP

3.893 M

YIELD

N/A

SHARES OUTSTANDING

1.224 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.42

PUBLIC FLOAT

AVERAGE 10 VOLUME

$11,966,018

AVERAGE 30 VOLUME

$3,440,694

Company detail

CEO: Steve N. Slilaty
Region: US
Website: sunshinebiopharma.com
Employees: 3
IPO year: 2010

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sunshine Biopharma focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement.

SBFM - Sunshine Biopharma Inc.